QURE - uniQure N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
39.35
+0.94 (+2.45%)
At close: 4:00PM EST

39.80 +0.45 (1.14%)
After hours: 5:42PM EST

Stock chart is not supported by your current browser
Previous close38.41
Open38.46
Bid33.00 x 800
Ask39.98 x 900
Day's range38.14 - 39.84
52-week range20.29 - 43.23
Volume351,050
Avg. volume356,018
Market cap1.466B
Beta (3Y monthly)1.07
PE ratio (TTM)N/A
EPS (TTM)-2.60
Earnings date30 May 2017 - 2 Jun 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est58.64
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced two recent online publications of preclinical studies showing significant silencing, or knockdown, of the mutated gene most commonly known to lead to onset of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two devastating neurodegenerative diseases. The proof-of-concept studies were conducted by uniQure scientists and utilized the Company’s miQURE™ technology, a proprietary, next-generation gene-silencing platform.

  • GlobeNewswire12 days ago

    uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B

    ~ Increases in FIX Activity Sustained at up to 51% of Normal, with Mean FIX of 38% of Normal at Twelve Weeks After Administration ~ ~ None of the Patients Received Factor.

  • GlobeNewswire16 days ago

    uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B

    LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it treated the first patient in its HOPE-B pivotal trial of AMT-061, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. AMT-061 has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency. “We are very pleased to have successfully administered AMT-061 to the first patient enrolled in the HOPE-B pivotal trial and mark this as a milestone for the field in advancing a potential one-time treatment for patients with hemophilia B,” said Robert Gut, M.D., Ph.D., chief medical officer of uniQure.

  • GlobeNewswire21 days ago

    uniQure to Participate in Multiple Upcoming Industry Conferences

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.

  • GlobeNewswire29 days ago

    uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 22, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AMT-130, and the IND is now effective allowing uniQure to begin its planned Phase I/II study.  AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients. “The FDA’s clearance of our IND for AMT-130 is a significant milestone for Huntington’s disease patients and an important event in the field of gene therapy,” said Matt Kapusta, chief executive officer at uniQure.

  • FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
    Zacks3 months ago

    FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101

    The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.

  • GlobeNewswire3 months ago

    uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated results from its ongoing Phase I/II trial of AMT-060, and provided an update on AMT-061, the Company’s next-generation gene therapy candidate currently in late-stage clinical development for patients with hemophilia B. AMT-060 is a first-generation gene therapy consisting of an AAV5 vector carrying a gene cassette with the wild-type FIX gene. The data on AMT-060 includes up to two and a half years of follow-up from the low-dose cohort and up to two years of follow-up from the second, higher-dose cohort.  These clinical data were presented on Sunday, December 2 in a poster presentation at the 59th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, California.

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within Vivint Solar, uniQure N.V, Internap, Intuit, WideOpenWest, and Deere — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma
    Investor's Business Daily3 months ago

    Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma

    Bayer announced Thursday it will cut 12,000 jobs amid a strategic overhaul to focus on its pharmaceuticals, consumer health and crop science businesses.

  • Novartis Gets Approval for Gene Therapy Luxturna in Europe
    Zacks3 months ago

    Novartis Gets Approval for Gene Therapy Luxturna in Europe

    Novartis (NVS) obtains EC approval for a one-time gene therapy, Luxturna for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65gene.

  • uniQure Stock Rose 35.7% Yesterday—Here’s Why
    Market Realist3 months ago

    uniQure Stock Rose 35.7% Yesterday—Here’s Why

    On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.

  • uniQure Up on Positive Data From Mid-Stage Hemophilia Study
    Zacks3 months ago

    uniQure Up on Positive Data From Mid-Stage Hemophilia Study

    uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.

  • A grandpa's hope for hemophilia cure leads him to gene therapy clinical trial
    CNBC3 months ago

    A grandpa's hope for hemophilia cure leads him to gene therapy clinical trial

    BioMarin's clinical trial of a gene therapy for hemophilia is providing hope to patients with the disease. It is an experimental treatment that uses a virus to deliver a healthy copy of a gene to make up for one that causes excessive bleeding.

  • Why uniQure N.V. Stock Is Skyrocketing Today
    Motley Fool3 months ago

    Why uniQure N.V. Stock Is Skyrocketing Today

    Great clinical results for its experimental hemophilia B gene therapy lit a fire beneath this biotech stock.

  • Options Traders Expect Huge Moves in uniQure (QURE) Stock
    Zacks3 months ago

    Options Traders Expect Huge Moves in uniQure (QURE) Stock

    uniQure (QURE) needs investors to pay close attention to the stock based on moves in the options market lately.

  • UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
    Zacks3 months ago

    UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates

    uniQure (QURE) delivered earnings and revenue surprises of 6.35% and -6.48%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    UniQure: 3Q Earnings Snapshot

    On a per-share basis, the Amsterdam-based company said it had a loss of 59 cents. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...